Log in

NYSE:SLS - Galena Biopharma Stock Price, Forecast & News

$3.07
+0.04 (+1.32 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$2.98
Now: $3.07
$3.25
50-Day Range
$2.95
MA: $4.00
$4.66
52-Week Range
$2.75
Now: $3.07
$82.50
Volume432,888 shs
Average Volume544,610 shs
Market Capitalization$14.96 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Develop biopharmaceuticals

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorHealth Technology
CUSIPN/A
WebN/A
Phone(917) 438-4353

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$14.96 million
Next Earnings Date3/27/2020 (Estimated)
OptionableNot Optionable

Receive SLS News and Ratings via Email

Sign-up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.


Galena Biopharma (NYSE:SLS) Frequently Asked Questions

What is Galena Biopharma's stock symbol?

Galena Biopharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "SLS."

How were Galena Biopharma's earnings last quarter?

Galena Biopharma, Inc. (NYSE:SLS) issued its quarterly earnings data on Thursday, November, 14th. The company reported ($2.68) earnings per share for the quarter. View Galena Biopharma's Earnings History.

When is Galena Biopharma's next earnings date?

Galena Biopharma is scheduled to release their next quarterly earnings announcement on Friday, March 27th 2020. View Earnings Estimates for Galena Biopharma.

Has Galena Biopharma been receiving favorable news coverage?

Media coverage about SLS stock has been trending negative on Saturday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Galena Biopharma earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Galena Biopharma.

Who are some of Galena Biopharma's key competitors?

What other stocks do shareholders of Galena Biopharma own?

Who are Galena Biopharma's key executives?

Galena Biopharma's management team includes the folowing people:
  • Angelos M. Stergiou, President, Chief Executive Officer & Director
  • Aleksey N. Krylov, Chief Financial Officer, Treasurer & Director
  • Nicholas J. Sarlis, Director, Chief Medical Officer & Senior VP
  • Barbara A. Wood, Secretary, Executive VP & General Counsel
  • Gregory M. Torre, Director, Chief Regulatory Officer & Senior VP

How do I buy shares of Galena Biopharma?

Shares of SLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Galena Biopharma's stock price today?

One share of SLS stock can currently be purchased for approximately $3.07.

How big of a company is Galena Biopharma?

Galena Biopharma has a market capitalization of $14.96 million. View Additional Information About Galena Biopharma.

How can I contact Galena Biopharma?

The company can be reached via phone at (917) 438-4353.


MarketBeat Community Rating for Galena Biopharma (NYSE SLS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  104 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  219
MarketBeat's community ratings are surveys of what our community members think about Galena Biopharma and other stocks. Vote "Outperform" if you believe SLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel